by Jen Hodson | May 31, 2019 | Press Releases
Preclinical and Clinical Data Demonstrate Advanced Deployment of Precision Medicine Tools to Analyze and Potentially More Effectively Intervene with Highly Focused Therapeutic Interventions Culver City, May 31, 2019 – NantKwest (Nasdaq:NK), a leading clinical-stage,...
by Jen Hodson | Feb 14, 2019 | Press Releases
Findings to be presented at the 2019 American Society of Clinical Oncology’s Genitourinary Cancers Symposium San Francisco and Culver City, CA – February 14, 2019 – Scientific teams from NantHealth (NASDAQ: NH) and NantOmics will present two posters at the American...
by Jen Hodson | Oct 29, 2018 | Press Releases
NantHealth’s Liquid GPS™ technology shows promise in the monitoring of key biomarkers in metastatic colorectal cancer MUNICH and CULVER CITY, CA – (October 29, 2018) — Significant developments in cancer research were presented by NantHealth...
by Jen Hodson | Aug 27, 2018 | Press Releases
Clinical Trial Tests Personalized Treatments in Push to Improve Pediatric Cancer Survival UCSF Benioff Children’s Hospitals are harnessing next-generation genomic technology to develop individualized drug cocktails in a new trial for children with a type of malignant...
by Jen Hodson | Aug 27, 2018 | Press Releases
Peer-reviewed research utilizing NantOmics technology gives scientists fresh insights into driving mechanisms behind a form of rare skin cancer. August 27,2018 – CULVER CITY, Calif — New, peer-reviewed research utilizing NantOmics technology, which powers...
by Jen Hodson | Jun 12, 2018 | Press Releases
7:02 pm MST | Jun 8, 2018 | BioCentury | Product Development POC FOR CYTOKINES Cytokines are emerging as a logical combination partner to boost PD-1 responses by Emily Cukier, Senior Writer Download Article...